U.S. FDA Grants Orphan Drug Designation to ABM-1310 for the Treatment of Patients with Glioblastoma Harboring BRAF V600 Mutation
- Written by PR Newswire
SAN DIEGO and SHANGHAI, Aug. 3, 2023 /PRNewswire/ -- ABM Therapeutics (ABM) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310, a novel small molecule BRAF inhibitor developed by the company, for the treatment of patients with glioblastoma (GBM) bearing BRAF V600...
Read more: U.S. FDA Grants Orphan Drug Designation to ABM-1310 for the Treatment of Patients with...














